Monthly Prescribing Reference23h
2024 Novel Drug and Biological Product Approvals
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
BioWorld3d
PH balance: Tenax outweighs pharmas with levosimendan heart bid
Publication on Dec. 12, 2024, of data analysis regarding Merck & Co. Inc.’s Winrevair (sotatercept) in Clinical Pharmacology & Therapeutics may have put investors in mind of the odds for the activin ...
FiercePharma5d
Regulatory tracker: Agios' Pyrukynd gets updated liver injury warning on its label
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
Pharmabiz6d
Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension
Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension: United Kingdom Friday, January 3, 2025, 17:00 Hrs ...
Hosted on MSN6d
UK MHRA approves MSD’s pulmonary arterial hypertension therapy
MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as ...
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair ...
What RFK Jr.’s Dislike for Drug TV Commercials Could Mean for the Ad Industry
Robert F. Kennedy Jr.’s stated desire to ban drug commercials from TV seems unlikely to become reality, according to advertising experts, but even pressure from Washington that falls short of an ...